Every 8-K that Lantern Pharma Inc. (LTRN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LTRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LTRN filings page.
Lantern Pharma Inc. (LTRN) received a Nasdaq notice that its common stock did not meet the $35,000,000 minimum market value of listed securities requirement after its market value stayed below that level for 30 consecutive business days. Nasdaq also said the company did not meet requirements under Listing Rules 5550(b)(1) and 5550(b)(3).
Lantern Pharma has 180 calendar days following the September 25, 2026 notice, through March 24, 2027, to regain compliance. If it seeks compliance through the market-value requirement, its market value must close at $35,000,000 or more for a minimum of 10 consecutive business days during that period. If the company does not regain compliance, it expects Nasdaq would notify it that its securities are subject to delisting from the Nasdaq Capital Market.
Lantern Pharma Inc. (LTRN) closed a registered direct offering on September 30, 2026, selling 1,469,725 common shares at $1.09 each and issuing pre-funded warrants for up to 2,200,000 shares at $1.0899 each. The company reported approximately $4.0 million in gross proceeds before placement-agent fees and other offering expenses; net proceeds are intended for working capital and general corporate purposes.
In a concurrent private placement, Lantern issued unregistered warrants for up to 3,669,725 shares at a $1.09 exercise price, potentially producing approximately $4 million in additional gross proceeds if fully exercised for cash. Exercise requires stockholder approval, and the warrants expire five years following the initial exercise date. They carry a 4.99% beneficial-ownership limit, or 9.99% at a holder’s election; an increase takes effect on the 61st day after election. Rodman & Renshaw acted as sole placement agent; Lantern paid a 7% cash fee on gross offering proceeds and issued placement-agent warrants to purchase 5% of the common shares or pre-funded warrants sold.
Lantern Pharma Inc. (LTRN) hosted a live webinar on September 23, 2026, discussing the Open-Medicine AI multi-agentic AI platform for drug development. A replay is available on YouTube and the company’s investor website, and the presentation used during the webinar was furnished as an exhibit.
Lantern Pharma Inc. (LTRN) is scheduled to present the growth plan for its wholly owned Open-Medicine AI subsidiary at a live webinar on September 23, 2026, at 12:30 PM Eastern. The 45-minute session is described as including a presentation, live demonstration, and Q&A, with discussion of market opportunity, customer feedback, roadmap, subscription and enterprise licensing economics, benchmarks, and partnerships under discussion.
Open-Medicine AI’s platform was first commercialized as withZeta.ai in April 2026 for rare and aggressive cancers; ZetaOmics, a computational biology module, was released to early-access users in July 2026. The company says it is extending the platform to additional disease categories, therapeutic modalities, and stages of drug development.
Lantern Pharma Inc. reported second-quarter 2026 results and a broad business update centered on its AI-driven oncology pipeline and new AI software subsidiary. Cash, cash equivalents and marketable securities were $7.4 million as of June 30, 2026, down from $10.1 million at year-end 2025, after receiving $4.4 million in gross proceeds from a May 2026 registered direct offering.
R&D expenses fell to $1.8 million from $3.1 million year over year, and loss from operations declined about 25% to $3.5 million. However, non-cash warrant-related expense of approximately $3.6 million drove net loss higher to $7.1 million (or $0.57 per share) versus $4.3 million a year earlier. The company stated it plans to pursue additional capital raises, collaborations and other opportunities to extend its operating runway.
Strategically, Lantern established Open Medicine AI as a wholly owned software subsidiary with executed commercial licenses and subscription customers, received EMA clearance for an investigator-initiated Phase 1b/2 bladder cancer trial of LP-184, advanced LP-300’s HARMONIC trial with an amended L858R-focused protocol, and continued development of LP-184, LP-284, and Starlight’s STAR-001 across multiple oncology indications.
Lantern Pharma Inc. announced the formal creation of Open-Medicine AI (OMAI) as a separate company to commercialize and expand its multi-agent AI co-scientist platform, previously launched as withZeta.ai. OMAI and Lantern have executed commercial licensing agreements, approved by Lantern’s Board and consistent with the framework outlined in Lantern’s May 2026 registered direct financing. These agreements grant OMAI access to Lantern’s withZeta.ai-related models, data, algorithms, and other assets and personnel, positioning OMAI for independent growth while preserving strategic alignment with Lantern’s clinical programs and shareholders.
OMAI will advance a multi-agentic architecture first proven in oncology and rare cancer research and extend it into broader disease areas. Lantern has established Centers of Excellence in Dallas, Texas and Bengaluru, India, with the Bengaluru AI Center of Excellence created in the first quarter of 2026 to support development, refinement, and scaling of the Open-Medicine platform. Lantern cites projections that the global AI drug discovery and development market could exceed $10 billion by 2030, with oncology as the largest segment and compound annual growth rates above 30 percent. The platform includes coordinated specialist agents, multiple research modes, proprietary rare-cancer knowledge bases, and tools such as ZetaOmics™ for multi-omic analysis and generative chemistry capabilities, and is intended to pursue a dedicated funding and valuation path distinct from Lantern’s clinical activities.
Lantern Pharma Inc. furnished an investor-style presentation used on June 1, 2026 to support discussions about the Harmonic™ Phase 2 clinical trial for its LP-300 product candidate. The presentation is attached as Exhibit 99.1 and is incorporated by reference for informational purposes.
The company notes that the material provided under this disclosure is considered "furnished," not "filed," which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
Lantern Pharma reported first quarter 2026 results showing tighter cost control while advancing its oncology and AI platforms. Research and development expenses fell to approximately $1.7 million, a 47% year-over-year reduction, and net loss narrowed to about $3.3 million, down 27%, or $0.30 per share.
Cash, cash equivalents, and marketable securities were about $6.3 million as of March 31, 2026, and a registered direct offering on May 14, 2026 added roughly $4.4 million in gross proceeds, which the company believes will fund operations into the middle of the first quarter of 2027.
Operationally, Lantern advanced its LP-300 HARMONIC trial with a successful FDA Type C meeting, obtained FDA IND clearance for Starlight Therapeutics’ pediatric CNS cancer trial, launched its multi-agentic AI co-scientist platform withZeta.ai commercially, expanded the predictBBB.ai platform, and outlined plans to separate withZeta.ai into an independent AI-focused entity.
Lantern Pharma Inc. entered into a registered direct offering and concurrent private placement raising approximately $4.4 million in gross proceeds. The company sold 1,454,175 common shares at $2.06 per share and issued pre-funded warrants for up to 681,748 shares at $2.0599 each, plus unregistered warrants to purchase up to 2,135,923 shares at an exercise price of $2.27 per share.
The warrants are exercisable starting six months after issuance and expire five years after first exercise, with exercise blocked above a 4.99% or 9.99% ownership cap. Lantern plans to use net proceeds for working capital and general corporate purposes. The company also outlined plans to separate its withZeta.ai AI platform and related assets into an independent entity that may seek its own stock exchange listing and give these investors rights to participate in up to 30% of certain future financings. Lantern agreed not to enter most variable-price financings for two years and temporarily suspended sales under its existing at-the-market program until a new prospectus supplement is filed.
Lantern Pharma Inc. furnished an investor presentation after using it in a live demonstration of withZeta.ai, the company’s multi-agentic AI co-scientist platform for rare cancer drug discovery, development, and clinical trial design. The session covered the platform’s capabilities, commercial architecture, rare cancer market opportunity, competitive positioning, and the company’s near-term revenue strategy and growth roadmap for withZeta.ai.
The presentation is provided as Exhibit 99.1 and a replay of the demonstration is available via an online link. Lantern highlights that the materials contain forward-looking statements about withZeta.ai’s potential advantages, development timelines, market opportunity, and planned use of AI, machine learning, and genomic data, and directs readers to existing risk factors in its latest Annual Report on Form 10-K.
Lantern Pharma Inc. reported narrower losses for 2025 while advancing its AI-driven oncology pipeline and platforms. Full-year net loss was about $17.1 million (or $1.57 per share), improving from roughly $20.8 million (or $1.93 per share) in 2024.
Research and development expenses fell to approximately $11.5 million, down 29%, while general and administrative costs rose modestly to about $6.5 million. Cash, cash equivalents and marketable securities were around $10.1 million as of December 31, 2025, and the company expects this to fund operations only until roughly late July to mid September 2026, so it is actively pursuing additional financing. During 2025 and early 2026 Lantern advanced multiple clinical programs, expanded its RADR® AI platform, launched the withZeta.ai co-scientist platform, and confirmed its CEO remains in place after refuting an online resignation rumor.
Lantern Pharma Inc. filed a current report describing an investor and stakeholder event held on January 22, 2026. During this event, the company used a presentation to support discussions and a live demonstration of its initial artificial intelligence tools and multi-agent system that are being developed to focus on rare cancers. The same presentation is furnished as Exhibit 99.1 to the report and is not treated as formally filed financial information. This update is intended to share information under Regulation FD, giving the market equal access to the materials used at the event.
Lantern Pharma (LTRN) reported administrative updates via Form 8-K related to third-quarter communications. The company will release financial results for the quarter ended September 30, 2025 and host a conference call and live webinar on November 13, 2025. A press release is furnished as Exhibit 99.1 and an investor presentation as Exhibit 99.2. These materials are furnished, not filed, under the Exchange Act, so they are not subject to Section 18 liability or automatically incorporated into other filings.
Lantern Pharma Inc. filed a Form 8-K reporting voting tallies for one or more matters. The record shows totals including 5,189,274 votes and several vote-category counts such as 2,212,199, 2,214,833, 2,213,670, 2,213,088, and smaller counts listed as Against 758,870, Against 43,732, and Abstain 29,603 and 26,426. The filing names Lantern Pharma Inc. as a Delaware corporation and is signed by David R. Margrave, Chief Financial Officer.
Lantern Pharma Inc. reported in a Current Report on Form 8-K dated August 13, 2025 that it will issue a press release announcing its financial results for the second quarter ended June 30, 2025. The Company furnished the press release as Exhibit 99.1 and included a cover page interactive data file as Exhibit 104.
The filing notes the disclosure is furnished, not filed, and therefore is not subject to Section 18 liability or incorporated by reference into other filings. The document identifies Lantern Pharma as an emerging growth company, indicates it elected not to use the extended transition period for new accounting standards, lists its Nasdaq ticker LTRN, principal executive office in Dallas, Texas, and is signed by CFO David R. Margrave.